Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 19.17% is 45% above its 5-year average of 13.22%, near the high end of its 5-year range (9.20%–19.17%).
As of the fiscal period ended Wednesday, December 31, 2025. 15.59% above its 12-month average of 16.59%.
Annual fiscal-year return on assets; no daily interpolation.
RETURN ON ASSETS (ROA)
19.17%
RETURN ON ASSETS (ROA) AVG TTM
16.59%
RETURN ON ASSETS (ROA) AVG 3Y
14.73%
RETURN ON ASSETS (ROA) AVG 5Y
13.22%
RETURN ON ASSETS (ROA) AVG 10Y
15.36%
RETURN ON ASSETS (ROA) AVG 15Y
13.69%
RETURN ON ASSETS (ROA) AVG 20Y
13.04%
CURRENT VS TTM AVG
+15.59%
CURRENT VS 3Y AVG
+30.10%
CURRENT VS 5Y AVG
+45.06%
CURRENT VS 10Y AVG
+24.80%
CURRENT VS 15Y AVG
+40.01%
CURRENT VS 20Y AVG
+46.96%
SECTOR MEDIAN · HEALTHCARE
4.93%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+288.84%
vs the sector median at left
United Therapeutics Corporation
Market Cap
$22.23B
Return on Assets (ROA)
19.17%
TTM Avg
16.59%
3Y Avg
14.73%
5Y Avg
13.22%
Market Cap
$22.14B
Return on Assets (ROA)
-27.80%
TTM Avg
-24.02%
3Y Avg
-10.32%
5Y Avg
-0.33%
Market Cap
$23.38B
Return on Assets (ROA)
-6.03%
TTM Avg
-3.96%
3Y Avg
9.16%
5Y Avg
17.06%
Market Cap
$20.80B
Return on Assets (ROA)
-0.80%
TTM Avg
-5.49%
3Y Avg
-1.68%
5Y Avg
-1.68%
Market Cap
$23.72B
Return on Assets (ROA)
13.86%
TTM Avg
12.54%
3Y Avg
14.20%
5Y Avg
14.86%
Market Cap
$25.02B
Return on Assets (ROA)
1.83%
TTM Avg
13.34%
3Y Avg
15.53%
5Y Avg
17.15%
Market Cap
$25.77B
Return on Assets (ROA)
4.93%
TTM Avg
4.41%
3Y Avg
4.42%
5Y Avg
6.18%
Market Cap
$18.52B
Return on Assets (ROA)
3.35%
TTM Avg
3.64%
3Y Avg
3.29%
5Y Avg
2.38%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | $22.23B | 19.17% | 16.59% | 14.73% | 13.22% |
| Moderna, Inc. (MRNA)vs › | $22.14B | -27.80% | -24.02% | -10.32% | -0.33% |
| STERIS plc (STE)vs › | $22.45B | 7.29% | 6.68% | 4.44% | 4.33% |
| BioNTech SE (BNTX)vs › | $23.38B | -6.03% | -3.96% | 9.16% | 17.06% |
| Viatris Inc. (VTRS)vs › | $20.80B | -0.80% | -5.49% | -1.68% | -1.68% |
| West Pharmaceutical Services, Inc. (WST)vs › | $23.72B | 13.86% | 12.54% | 14.20% | 14.86% |
| Waters Corporation (WAT)vs › | $25.02B | 1.83% | 13.34% | 15.53% | 17.15% |
| Labcorp Holdings Inc. (LH)vs › | $25.77B | 4.93% | 4.41% | 4.42% | 6.18% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.52B | 3.35% | 3.64% | 3.29% | 2.38% |
| Incyte Corporation (INCY)vs › | $25.96B | 19.51% | 9.54% | 8.43% | 7.44% |
ROA
19.2%
ROE
21.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 16.94% |
| 2024-12-31 | 16.23% |
| 2023-12-31 | 13.74% |
| 2022-12-31 | 12.03% |
| 2021-12-31 | 9.20% |
| 2020-12-31 | 11.15% |
| 2019-12-31 | -2.67% |
| 2018-12-31 | 17.32% |
| 2017-12-31 | 14.51% |
| 2016-12-31 | 30.69% |
| 2015-12-31 | 29.83% |
| 2014-12-31 | 18.05% |
| 2013-12-31 | 8.36% |
| 2012-12-31 | 18.72% |
| 2011-12-31 | 14.35% |
| 2010-12-31 | 7.40% |
| 2009-12-31 | 1.85% |
| 2008-12-31 | -4.91% |
| 2007-12-31 | 3.38% |
| 2006-12-31 | 15.46% |
| 2005-12-31 | 22.31% |
| 2004-12-31 | 7.46% |
| 2003-12-31 | -5.55% |
| 2002-12-31 | -12.81% |
| 2001-12-31 | -17.58% |
| 2000-12-31 | -30.17% |
| 1999-12-31 | -55.93% |
| 1998-12-31 | -68.45% |
